HDAC4 and neoplasm: This aligns with prior reports indicating that tasquinimod's cell viability effects typically occur at micromolar concentrations, consistent with its primary mechanism of action targeting tumour microenvironment modulation (e.g., angiogenesis, immune evasion) via HDAC4 inhibition rather than direct tumour cell killing [33].